Azafaros

News

Azafaros is set to start phase 3 trials of its lead drug for a trio of rare lysosomal storage disorders, backed by €132m in new Series B financing.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.